AI assistant
Pharnext — Report Publication Announcement 2017
Sep 28, 2017
1594_iss_2017-09-28_81a8839a-f063-4e2a-b25d-3336142d73b3.pdf
Report Publication Announcement
Open in viewerOpens in your device viewer
Press Release
Pharnext to Present at 4 th International Neurotech Investing and Partnering Conference
Paris, France, 5:45pm, September 28, 2017 (CEST) – Pharnext SA (FR00111911287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a corporate overview at the 4th International Neurotech Investing and Partnering Conference.
The presentation will take place as follows:
- Date: Wednesday, October 4 th, 2017
- Time: 4:00pm CEST
- Venue: Wyss Center in Geneva, Switzerland
If you are interested in meeting the Pharnext management team during this event, please send an email to Anne Hennecke at [email protected].
About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer's disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR00111911287). For more information, visit www.pharnext.com
CONTACTS:
Pharnext Xavier Paoli Chief Commercial Officer [email protected] +33 (0)1 41 09 22 30
Investor Relations (Europe) MC Services AG Anne Hennecke [email protected] +49 211 529252 22
Media Relations (Europe) ALIZE RP Caroline Carmagnol Margaux Pronost [email protected] +33 (0)1 44 54 36 64
Investor Relations (U.S.) Stern Investor Relations, Inc. Matthew Shinseki [email protected] +1 212 362 1200
Media Relations (U.S.) RooneyPartners Marion Janic [email protected] +1 212 223 4017
Financial Communication (France) Actifin Stéphane Ruiz [email protected] +33 (0)1 56 88 11 15